CTOs on the Move


 
SpaLab, Inc. is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.spalab.com
  • 1125 Linda Vista Dr Ste 106
    San Marcos, CA USA 92078
  • Phone: 888.633.0012

Executives

Name Title Contact Details

Similar Companies

Triangle Compounding Pharmacy

Triangle Compounding Pharmacy is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turing Pharmaceuticals

Turing Pharmaceuticals is a fully integrated biopharmaceutical company focusing on patients with unmet medical needs. We are dedicated to helping patients, who often have no effective treatment options, by developing and commercializing innovative treatments.

Crestwyn Behavioral Health

Crestwyn Behavioral Health, the preferred acute inpatient psychiatric hospital in Memphis, TN, treating mental health disorders in adults & adolescents.

Visus Therapeutics

Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.